EPIC™ MITRAL AND AORTIC STENTED TISSUE VALVES
The Epic Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, and a future-forward design that gives you and your patients more choices when it comes to preserving long-term treatment paths.
EPIC™ MITRAL AND AORTIC STENTED TISSUE VALVES
The Epic Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, and a future-forward design that gives you and your patients more choices when it comes to preserving long-term treatment paths.
TREATING TODAY, PRESERVING TOMORROW
This generation of the Epic Platform has been built on the Biocor legacy of excellent durability, proven performance and unparalleled implantability—and reimagined with the future of transcatheter interventions in mind.
It’s the surgical valve platform that gives you and your patients more choices when it comes to preserving long-term treatment paths.
MITRAL
- Low stent post height is less likely to obstruct the left ventricular outflow tract (LVOT)1
- Epic valve leaflets are not prone to forming a curtain between stent posts when opened; curtaining can result in LVOT obstruction
AORTIC
- Can withstand up to approximately 8 atm pressure during balloon valvuloplasty procedures3
- Internally mounted leaflets and low stent post height reduce coronary obstruction4
*For 27 mm valve size, measured from the farthest point of the cuff.
- Streamlined Customizable Implantation
- Stent symmetry eliminates the need for specific orientation2
- Flexible polymer stent offers more forgiving insertion and seating
- Short rinse time of 2 x 10 seconds2
- Epic Mitral valve ratcheting holder reduces risk of suture looping and offers a true one-cut release
- Epic Platform cuff options allow for secure suture placement while limiting suture drag and parachuting forces
- Exceptional durability across patient populations
Linx™ anticalcification (AC) treatment may improve long-term performance and durability.*
10 YEARS
97.3 ± 0.5%†
Freedom from SVD,
all patient ages
(Epic Aortic VALVE)595.7 ± 2.6%†
Freedom from SVD,
all patient ages
(Epic Mitral VALVE)5*There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.
†From stand-alone aortic or mitral valve replacements.
PATIENTS WHO BENEFIT
Surgical valve treatment for mitral and aortic valve disease
The Epic™ Mitral stented tissue valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native mitral heart valve. It may also be used to replace a previously implanted prosthetic mitral valve.
The Epic™ Supra stented tissue valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic heart valve. It may also be used to replace a previously implanted prosthetic aortic valve.
Data suggest many patients with degenerative mitral valve disease do not receive state-of-the-art care.6 While mitral valve repair is typically the treatment of choice to treat mitral valve dysfunction, it is not always feasible.
- Considerations when selecting bioprosthestic valve candidates7
A bioprosthetic mitral or aortic valve may be a recommended option for patients under the following AHA/ACC treatment guidelines7:
- Patients with a contraindication for anticoagulation therapy or an anticipated nonadherence or inability to regulate vitamin K antagonists
- Patients over 70 years of age
- For patients 50-65 years of age, there is no clear consensus on choosing a mechanical vs a tissue valve; newer-generation tissue prostheses may show greater freedom from structural deterioration, often for older patients
Mitral valve replacement
- Chronic, severe mitral regurgitation (MR) patients undergoing cardiac surgery for other indications7
- Symptomatic patients with chronic, severe MR (stage D) and left ventricular ejection fraction (LVEF) > 30%7
- Asymptomatic patients with chronic, severe MR and LV dysfunction (LVEF 30%-60% and/or LV end-systolic diameter ≥ 40 mm, stage C2)8
- Advanced endocarditis8
Aortic valve replacement
- Symptomatic patients with severe aortic stenosis (AS) (Stage D) who meet an indication for aortic valve replacement with low-to-intermediate surgical risk7
- Asymptomatic patients with severe AS (Stage C) who meet an indication for aortic valve replacement with low-to-intermediate surgical risk7
- Severe AS (stage C or D) when undergoing cardiac surgery for other indications when there is decreased systolic opening of a calcified aortic valve with an aortic velocity ≥ 4.0 m per second or mean pressure gradient ≥ 40 mmHg7
KEY FEATURES
The Platform for Possibility
The Epic™ Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, a future-forward design, and more. The platform boasts the low ventricular protrusion in all valve sizes, a flexible polymer stent, individually selected porcine leaflets to ensure optimal coaptation, and a flexible sewing cuff designed to minimize both in-implant suture drag and post-implant paravalvular leak.
- Epic™ Supra Aortic Stented Tissue Valve Features
- Silicone-Filled Cuff
- FlexFitTM Polymer Stent
- Unique Pericardial Shield
- Flexible Cuff
- Low Stent Post Height
Allows for supra-annular implantation
- Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
- Eases implant
- Accommodates MIS procedures
Provides a tissue-to-tissue interface to help prevent the risk of abrasion
Mitigates PVL and easily fits patient anatomy
Mitigates risk of coronary obstruction
EPIC™ SUPRA AORTIC STENTED TISSUE VALVE FEATURES
12345SILICONE-FILLED CUFF
Allows for supra-annular implantation
FLEXFIT™ POLYMER STENT
- Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
- Eases implant
- Accommodates MIS procedures.
UNIQUE PERICARDIAL SHIELD
Provides a tissue-to-tissue interface to help prevent the risk of abrasion
FLEXIBLE CUFF
Mitigates PVL and easily fits patient anatomy
LOW STENT POST HEIGHT
Mitigates risk of coronary obstruction
- Epic™ Mitral Stented Tissue Valve Features
- Optimal Leaflet Design and Matching
- Low Ventricular Protrusion
- FlexFitTM Polymer Stent
- Unique Pericardial Shield
- Flexible Cuff
- Ratcheting Holder
Reduces regurgitation risk
Avoids LVOT obstruction
- Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
- Eases implant
- Accommodates MIS procedures.
Provides a tissue-to-tissue interface to help prevent the risk of abrasion
Mitigates PVL and easily fits patient anatomy
Streamlines implant and reduces risk of suture looping
EPIC™ MITRAL STENTED TISSUE VALVE FEATURES
123456OPTIMAL LEAFLET DESIGN AND MATCHING
Reduces regurgitation risk
LOW VENTRICULAR PROTRUSION
Avoids LVOT obstruction
FLEXFIT™ POLYMER STENT
- Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
- Eases implant
- Accommodates MIS procedures.
UNIQUE PERICARDIAL SHIELD
Provides a tissue-to-tissue interface to help prevent the risk of abrasion
FLEXIBLE CUFF
Mitigates PVL and easily fits patient anatomy
RATCHETING HOLDER
Streamlines implant, reduces risk of suture looping, and offers true one cut holder release
- Flexible Design Now and Later
Curtaining is a characteristic of bioprosthetic valves in which the leaflets, when opened, stand tall or form a “curtain” between stent posts.9,* Epic Mitral leaflets are not prone to curtaining, which can result in less LVOT obstruction.9,*
Leaflet behavior when opened
25 mm Epic Mitral valve (left) and Magna Mitral Ease‡ (right), with representative rods inserted *Results based on internal testing.
‡Indicates a third-party trademark, which is property of its respective owner. - Preserving the LVOT
*For 27 mm valve size, measured from the farthest point of the cuff.
†Indicates a third-party trademark, which is property of its respective owner. - Anticalcification Advantages
Abbott’s unique Linx AC technology—to promote anticalcification*—is designed to improve long-term performance and valve durability. The Linx AC treatment has demonstrated resistance to calcification by:
- Extracting lipids12
- Reducing free aldehydes13,14
- Minimizing cholesterol uptake15
- Stabilizing leaflet collagen15
*No clinical data currently available have evaluated the long-term impact of anticalcification tissue treatment in humans.
MAT-2006197 v.4.0 | Item approved for OUS use only.